Prasugrel Tablet, Film Coated
Product Images NDC 63629-4829

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Prasugrel (NDC 63629-4829). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636294829)

Each film-coated tablet contains 10 mg of Prasugrel Hydrochloride USP. Prasugrel tablets should be stored at 20° to 25°C (68° to 77°F) and dispensed with the Medication Guide to the patient. It is important to keep the medication out of reach of children and not to use if the inner seal is missing or broken. This information is provided by Bryant Ranch Prepack, Inc. and manufactured by Aurobindo Pharma Limited.*

FDA Label Image

Figure 1: Non-cabg-related Timi Major Or Minor Bleeding Events. (Prasugrel Fig1)

FDA Label Image

Figure 2: Inhibition (mean±sd) Of 20 μm Adp-induced Platelet Aggregation (ipa) Measured By Light Transmission Aggregometry After Prasugrel 60 mg. (Prasugrel Fig2)

This is a table providing information on platelet aggregation under different conditions such as ADP concentration and time. The data includes mean and standard deviation values as well. It seems to be a study or experiment related to platelet function.*

FDA Label Image

Figure 3: Time To First Event Of Cv Death, Mi, Or Stroke (triton-timi 38). (Prasugrel Fig3)

This text appears to contain information related to the comparison of the effectiveness of two types of medications, Clopidogrel and Prasugrel, in reducing the risk of cardiovascular events such as cardiovascular death, nonfatal myocardial infarction (MI), and nonfatal stroke over a certain period of time. The data is presented in a format that includes the number of events and the corresponding percentages for each medication at different time points from randomization. The graph possibly illustrates the incidence of events over days from randomization for both medications.*

FDA Label Image

Figure 4: Subgroup Analyses For Time To First Event Of Cv Death, Mi, Or Stroke (hr And 95% Ci; Triton-timi 38) – Ua/nstemi Patients. (Prasugrel Fig4)

This evaluation provides a comparison between Prasugrel and Clopidogrel in different baseline characteristics of patients with UA/NSTEMI events. The data includes information on demographics such as age and gender, as well as details on body weight, region, medical history (like diabetes, metabolic syndrome, previous MI, PCI, CABG, and TIA/Stroke), time from symptom onset, stent type used, and use of GP IIb/IIIa inhibitor. The analysis also presents hazard ratio information, indicating which medication might be more effective in certain situations.*

FDA Label Image

Figure5 (Prasugrel Fig5)

This is a summary of baseline characteristics for a study comparing the efficacy of Prasugrel and Clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI). The table includes information on demographics (age and gender), body weight, region, comorbidities (diabetes mellitus, metabolic syndrome, previous heart procedures), time from symptom onset, stent type, and use of medication (GP IIb/IIIa inhibitors). The hazard ratio suggests Prasugrel may be more beneficial compared to Clopidogrel.*

FDA Label Image

Chemical Structure (Prasugrel Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.